Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ralinepag in pulmonary arterial hypertension
NL-OMON60837Phase 3Active, not recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoint: Long-term safety and tolerability of ralinepag. Started Nov 2020; status: active, not recruiting.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON60837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60837.